Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment

Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments (Novo Nordisk)